SYNERGY: Mirabegron has obtained the drug registration certificate in South Korea
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, SYNERGY announced that the company recently received the Mirabegron drug registration certificate issued by the Ministry of Food and Drug Safety (MFDS) of South Korea. Mirabegron is a selective β3-adrenergic receptor agonist that can improve bladder filling and storage capacity by activating β3-adrenergic receptors on the bladder detrusor muscle. It is clinically used to treat symptoms of overactive bladder, such as urgency urinary incontinence, urinary urgency, and urinary frequency
According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that the company recently received the Mirabegron drug registration certificate issued by the Ministry of Food and Drug Safety (MFDS) of South Korea. Mirabegron is a selective β3-adrenergic receptor agonist that can enhance bladder filling and storage capacity by activating β3-adrenergic receptors on the bladder detrusor muscle, and is clinically used to treat symptoms of overactive bladder such as urgency urinary incontinence, urinary urgency, and urinary frequency